The chief scientific officer of the CMT Research Foundation discussed investigative cell and gene therapy approaches for treating CMT.
Keith Fargo, PhD
Advertisement
Articles by Keith Fargo, PhD
The chief scientific officer of the CMT Research Foundation discussed the foundation ’s mission.
Advertisement
Latest Updated Articles
Uptake of Nononcology Gene Therapy Remains Slow in HematologyPublished: August 16th 2024 | Updated: August 19th 2024
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLDPublished: March 18th 2024 | Updated: June 3rd 2024
Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 DataPublished: December 7th 2024 | Updated:
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell TherapyPublished: December 12th 2022 | Updated:
RPE Cell Therapy Shows Improvements in Early GA With AMDPublished: July 14th 2024 | Updated:
Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of VisionPublished: May 18th 2023 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Patients With DMD Treated With Avidity Biosciences’ Antibody Oligonucleotide Conjugate Del-Zota Show Functional Improvements
2
In Response to FDA’s Release of Full CRL for Deramiocel, Capricor Publishes Full Response to the Agency
3
Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
4
